Lexaria Bioscience (LXRP, CNSX:LXX) Rubs Elbows With Some Impressive Names
Lexaria Bioscience Corp (OTCMKTS:LXRP, CNSX:LXX) has inked a development deal with none other than the Canadian government's top research division... and the government is chipping in some money.
By Bryan Murphy
Feb 8, 2017 7:10:25 AM PST | No Comment(s) - Post a Comment Rating
Print Email
StockHQ:
LXRP $0.55 +$0.04 +7.84%
You can tell a lot about a company by the company it keeps. That's why the news from Lexaria Bioscience Corp (OTCMKTS:LXRP, CNSX:LXX) should turn heads. The organization is teaming up with the National Research Council of Canada (NRC) to further develop its bioavailability science. It's a big -- and telling -- deal simply because with the National Research Council of Canada is "the Government of Canada's premier research and technology organization (RTO)." Not a bad friend to have.
Of course, given the science Lexaria Bioscience has developed, news of a master collaborative research agreement comes as no real surprise.
For those not familiar with it, Lexaria has developed and patented a proprietary technology that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, though Lexaria is starting with hemp as it's the most underserved market and arguably the biggest growth opportunity.
The game-changer is that Lexaria Bioscience is able to combine whatever molecules it wants with lipids -- or fatty acids -- at the molecular level. It matters, because the human endocannabinoid system is itself lipid based, making this format the easiest and most effective means of introducing vitamins, minerals, medicines, and more.
The science works, too - two different studies have been done to support the claim.
The first study -- a third party review and in-vitro assessment of cannabidiol (CBD) bioabsorption done late last year -- indicated up to a 499% improvement in absorption compared to what was currently achievable. The second study performed earlier this year was a human clinical trial of nitric oxide induction. This study demonstrated potent CBD bioabsorption in humans using a nitricoxide salivary biomarker test. All subjects demonstrated rapid, significant and sustained increase in salivary nitric oxide levels (a 500%-1000% increase) following product ingestion.
Others have taken notice, and become interested in seeing just how far the proprietary science can go. The National Research Council of Canada is one of those that's taken interest, including financially. It's committed $125,00 (matching Lexaria's contribution)to " investigate technical aspects and new opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions." The collaboration will investigate and define the chemical nature of the molecular association that Lexaria`s patented technology is believed to effectuate between lipophilic active agents and fatty acids as solubility and bioavailability enhancing agents. Effective delivery of lipophilic active agents spans across industry sectors such as, food, vitamins, pharmacy and more, which are multi-billion dollar opportunities.
Lexaria Bioscience believes this research -- and the partnership itself -- will ultimately lead to more licensing agreements. It's not a bad assumption either. The non-profit NCR lends a lot of credibility to the work Lexaria has done to date.
For more on Lexaria, visit the company website here.
